Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PCRX by emailGet an email when PCRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PCRX, unsubscribe in one click. Privacy
📣 What PCRX Says Is Next
by the end of 2026 · “Enrollment in Part A concluded in June, with topline data expected by the end of 2026.”
Company press release, Aug 4, 2026 · SEC filing
this year · “The company expects to report topline results later this year.”
Company press release, Apr 30, 2026 · SEC filing
the end of 2026 · “The company expects to report topline results from Part A of the study near the end of 2026.”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PCRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PCRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.